Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry

Blood (2024) 144 (Supplement 1): 3059.

https://doi.org/10.1182/blood-2024-200073

Published: 2024

Journal Articles

Scoring System Using Age, C-Reactive Protein, Hemoglobin, and Albumin (ACHA) For Predicting Outcomes Of Diffuse Large B-Cell Lymphoma In The Rituximab-Era

Hirotsugu Ariizumi, MD, Bungo Saito, MD, Eisuke Shiozawa, MD, Yui Uto, MD, Norimichi Hattori, MD, Kouji Yanagisawa, MD, Hidetoshi Nakashima, MD, Hiroshi Harada, MD, Hiraku Mori, MD, Tsuyoshi Nakamaki, MD

Blood (2013) 122 (21): 4305.

https://doi.org/10.1182/blood.V122.21.4305.4305

Published: 2013

Journal Articles

Analysis of CD20-Mediated Signals in Refractory Diffuse Large B-Cell Lymphoma Cells.

Tsuyoshi Nakamaki, MD, Kunihiko Fukuchi, Hidetoshi Nakashima, MD, Hirotsugu Ariizumi, MD, Takashi Maeda, MD, Bungo Saito, MD, Kouji Yanagisawa, MD, Shigeru Tomoyasu, MD

Blood (2012) 120 (21): 2684.

https://doi.org/10.1182/blood.V120.21.2684.2684

Published: 2012

Journal Articles

Inhibition of Phosphatidylinositol 3-Kinase Is Effective to Suppress the Growth of CD20-Negative Refractory Diffuse Large B-Cell Lymphoma Cells

Tsuyoshi Nakamaki, MD, Kunihiko Fukuchi, MD, Hidetoshi Nakashima, MD, Hirotsugu Ariizumi, MD, Takashi Maeda, MD, Bungo Saito, MD, Kouji Yanagisawa, MD, Shigeru Tomoyasu, MD, Eisuke Shiozawa, MD, Toshiko Yamochi-Onizuka, MD, Hidekazu Ota, MD

Blood (2011) 118 (21): 2421.

https://doi.org/10.1182/blood.V118.21.2421.2421

Published: 2011

Journal Articles

Constitutive Cyclin A1 Expression Induces Abrogation of Cell Cycle Check Points Associated with Ara-C Resistance in Myeloid Leukemia Cells.

Tsuyoshi Nakamaki, Kunihiko Fukuchi, Norimichi Hattori, Hidetoshi Nakashima, Takashi Maeda, Kouji Yanagisawa, Bungo Saito, Isao Matsuda, Shigeru Tomoyasu

Blood (2009) 114 (22): 4801.

https://doi.org/10.1182/blood.V114.22.4801.4801

Published: 2009

Journal Articles

Constitutive Cyclin A1 Expression Inhibits Cytosine Arabinoside-Induced Apoptosis in Myeloid Leukemia Cells.

Tsuyoshi Nakamaki, MD, Kunihiko Fukuchi, Hidetoshi Nakashima, Norimichi Hattori, Takashi Maeda, Hirotsugu Ariizumi, Daisuke Adachi, Bungo Saito, Takaji Yanagisawa, Isao Matsuda, Shigeru Tomoyasu

Blood (2008) 112 (11): 3370.

https://doi.org/10.1182/blood.V112.11.3370.3370

Published: 2008

Journal Articles

Characterization of Double BCR-ABL–positive Cell Lines Established from a Patient with Blasic Crisis of Chronic Myeloid Leukemia Who Showed Clinical Resistant to Imatinib

Tsuyoshi Nakamaki, Norimichi Hattori, Hidetoshi Nakashima, Takashi Maeda, Hirotsugu Ariizumi, Shigeru Tomoyasu

Blood (2008) 112 (11): 4244.

https://doi.org/10.1182/blood.V112.11.4244.4244

Published: 2008

Journal Articles

Increased Expression of Cyclin A1 mRNA Is a Novel Adverse Prognostic Indicator for Acute Promyelocytic Leukemia in Differentiation Therapy by All- Trans Retinoic Acid.

Tsuyoshi Nakamaki, MD, Hidetoshi Nakashima, MD, Masamichi Hattori, MD, Takako Usui, MD, Mayumi Honma, MD, Daisuke Adachi, MD, Bungo Saito, MD, Shigeru Tomoyasu, MD

Blood (2006) 108 (11): 2344.

https://doi.org/10.1182/blood.V108.11.2344.2344

Published: 2006

Journal Articles

Treatment Effect of Rituximab Plus Chemotherapy Is Obtained by Improving Survival from Non-Germinal Center-Type Untreated Diffuse Large B-Cell Lymphoma.

Bungo Saito, MD, Eisuke Shiozawa, M.D, Takako Usui, M.D, Hidetoshi Nakashima, M.D, Takashi Maeda, M.D, Norimichi Hattori, M.D, Daisuke Adachi, M.D, Toshiko Yamochi-Onizuka, M.D, Masafumi Takimoto, M.D, Tsuyoshi Nakamaki, M.D, Hidekazu Ota, M.D, Shigeru Tomoyasu, M.D

Blood (2006) 108 (11): 2032.

https://doi.org/10.1182/blood.V108.11.2032.2032

Published: 2006

Journal Articles

Altered Expressions of CD30, c-Jun N-Terminal Kinase, NF-κB and JunB Are Involved in Disease Progression in CD30-Positive Anaplastic Large Cell Lymphoma.

Tsuyoshi Nakamaki, MD, Hidetoshi Nakashima, MD, Masamichi Hattori, MD, Takako Usui, MD, Takashi Maeda, MD, Kunihiko Fukuchi, MD, Shigeru Tomoyasu, MD

Blood (2005) 106 (11): 2827.

https://doi.org/10.1182/blood.V106.11.2827.2827

Published: 2005

Journal Articles

Analysis of Factors Involved in Malignant Progression of Anaplastic Large Cell Lymphoma Kinase (ALK) -Negative Anaplastic Large Cell Lymphoma.

Tsuyoshi Nakamaki, MD, Takashi Maeda, MD, Hidetoshi Nakashima, MD, Masamichi Hattori, MD, Takako Usui, MD, Shigeru Tomoyasu, MD, Yoshio Honma, PhD

Blood (2004) 104 (11): 3272.

https://doi.org/10.1182/blood.V104.11.3272.3272

Published: 2004

NARROW

Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry

Scoring System Using Age, C-Reactive Protein, Hemoglobin, and Albumin (ACHA) For Predicting Outcomes Of Diffuse Large B-Cell Lymphoma In The Rituximab-Era

Analysis of CD20-Mediated Signals in Refractory Diffuse Large B-Cell Lymphoma Cells.

Inhibition of Phosphatidylinositol 3-Kinase Is Effective to Suppress the Growth of CD20-Negative Refractory Diffuse Large B-Cell Lymphoma Cells

Constitutive Cyclin A1 Expression Induces Abrogation of Cell Cycle Check Points Associated with Ara-C Resistance in Myeloid Leukemia Cells.

Constitutive Cyclin A1 Expression Inhibits Cytosine Arabinoside-Induced Apoptosis in Myeloid Leukemia Cells.

Characterization of Double BCR-ABL–positive Cell Lines Established from a Patient with Blasic Crisis of Chronic Myeloid Leukemia Who Showed Clinical Resistant to Imatinib

Increased Expression of Cyclin A1 mRNA Is a Novel Adverse Prognostic Indicator for Acute Promyelocytic Leukemia in Differentiation Therapy by All- Trans Retinoic Acid.

Treatment Effect of Rituximab Plus Chemotherapy Is Obtained by Improving Survival from Non-Germinal Center-Type Untreated Diffuse Large B-Cell Lymphoma.

Altered Expressions of CD30, c-Jun N-Terminal Kinase, NF-κB and JunB Are Involved in Disease Progression in CD30-Positive Anaplastic Large Cell Lymphoma.

Analysis of Factors Involved in Malignant Progression of Anaplastic Large Cell Lymphoma Kinase (ALK) -Negative Anaplastic Large Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only